Component 416

VYNDAMAX can help people with transthyretin cardiac amyloidosis (ATTR-CM) live longer

  • VYNDAMAX* was studied in the Tafamidis in Transthyretin Amyloidosis Cardiomyopathy Clinical Trial (known as ATTR-ACT)
  • The study tested if VYNDAMAX could help people with ATTR-CM live longer and reduce hospitalizations due to heart problems compared to placebo
  • The study also tested the impact of VYNDAMAX on quality of life and ability to function

*The clinical studies of VYNDAQEL® (a different form of tafamidis) supported the approval of VYNDAMAX. Both drugs contain the same active ingredient.

How was VYNDAMAX studied?

The safety and efficacy of VYNDAMAX was studied in a 30-month clinical study of 441 adult patients with wild-type or hereditary ATTR-CM.

  • The VYNDAMAX study primarily focused on the reduction of death and heart-related hospitalizations and safety
  • VYNDAMAX was also assessed on other aspects of ATTR-CM, including walking speed (6-Minute Walk Test) and health-related quality of life
  • Efficacy and safety were determined by comparing patients treated with VYNDAMAX (n=264) with patients who did not take VYNDAMAX (placebo) (n=177)
  • Patients were evaluated every 6 months for a total of 30 months
Survival rate at month 30

AFTER 21/2YEARS

more people were alive taking VYNDAMAX than placebo

VYNDAMAX can help lower the risk of hospitalizations related to heart problems

  • In the study, patients taking VYNDAMAX had fewer heart-related hospitalizations than those in the placebo group

32% LOWER RISK
of hospitalizations related to heart problems

Remember that even if you don’t feel it working, always take VYNDAMAX as prescribed. It’s important to tell your doctor how you are feeling.

Health-related quality of life measured in people taking VYNDAMAX

The Kansas City Cardiomyopathy Questionnaire (KCCQ) was used to measure health-related quality of life.

At the end of the 30-month clinical trial, compared to people not on treatment (placebo group), people taking VYNDAMAX reported:

Better quality of life

(mental health status, enjoyment of life)

Fewer heart-related symptoms

(shortness of breath, fatigue, swollen feet, or ankles)

More comfort performing daily activities

(ability to perform social and physical activities)

Patients in the VYNDAMAX and placebo groups had worse KCCQ overall summary scores at month 30 than at the start of the study.

Heart function and exercise capacity measured in patients taking VYNDAMAX

The 6-Minute Walk Test (6MWT) measured heart function and exercise capacity.

At 30 months, people who took VYNDAMAX were able to walk 83 yards (76 meters) farther on average than people who did not take VYNDAMAX (placebo).†

†Patients in the VYNDAMAX and placebo groups had worse 6-minute walking distance than at the start of the study

Watch to learn how VYNDAMAX can impact ATTR-CM

Create a discussion guide to help you log your symptoms and talk to your doctor about ATTR-CM

GET STARTED
CARDIOLOGIST RECOMMENDED

VYNDAMAX is the only treatment with a Class 1‡ recommendation for ATTR-CM in guidelines from:

  • American College of Cardiology
  • American Heart Association
  • Heart Failure Society of America

‡Class 1 guidelines are given when there’s strong evidence or general agreement that a treatment is beneficial, useful, and effective. The above recommendation is from the 2022 guidelines. As of September 2024, VYNDAMAX is the only treatment approved for ATTR cardiac amyloidosis.

Explore how VYNDAMAX works